Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
1982
134
LTM Revenue $12.0M
LTM EBITDA n/a
$67.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Accelerate Diagnostics has a last 12-month revenue of $12.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Accelerate Diagnostics achieved revenue of $12.1M and an EBITDA of -$49.8M.
Accelerate Diagnostics expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Accelerate Diagnostics valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $12.8M | $12.1M | $11.9M | $12.0M | XXX |
Gross Profit | -$0.4M | $3.3M | $2.5M | XXX | XXX |
Gross Margin | -3% | 27% | 21% | XXX | XXX |
EBITDA | -$55.8M | -$49.8M | n/a | n/a | XXX |
EBITDA Margin | -438% | -413% | NaN% | 0% | XXX |
Net Profit | -$77.7M | -$62.5M | -$61.6M | XXX | XXX |
Net Margin | -609% | -518% | -518% | XXX | XXX |
Net Debt | $68.2M | $38.4M | $24.7M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 14, 2025, Accelerate Diagnostics's stock price is $1.
Accelerate Diagnostics has current market cap of $29.6M, and EV of $67.6M.
See Accelerate Diagnostics trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$67.6M | $29.6M | XXX | XXX | XXX | XXX | $-2.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 14, 2025, Accelerate Diagnostics has market cap of $29.6M and EV of $67.6M.
Accelerate Diagnostics's trades at 5.7x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Accelerate Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Accelerate Diagnostics and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $67.6M | XXX | XXX | XXX |
EV/Revenue | 5.7x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAccelerate Diagnostics's NTM/LTM revenue growth is 3%
Accelerate Diagnostics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Accelerate Diagnostics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Accelerate Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Accelerate Diagnostics and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -1% | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 210% | XXX | XXX | XXX | XXX |
Opex to Revenue | 469% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Philips | XXX | XXX | XXX | XXX | XXX | XXX |
Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Electromed | XXX | XXX | XXX | XXX | XXX | XXX |
InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Accelerate Diagnostics acquired XXX companies to date.
Last acquisition by Accelerate Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Accelerate Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Accelerate Diagnostics founded? | Accelerate Diagnostics was founded in 1982. |
Where is Accelerate Diagnostics headquartered? | Accelerate Diagnostics is headquartered in United States of America. |
How many employees does Accelerate Diagnostics have? | As of today, Accelerate Diagnostics has 134 employees. |
Who is the CEO of Accelerate Diagnostics? | Accelerate Diagnostics's CEO is Mr. John Phillips. |
Is Accelerate Diagnostics publicy listed? | Yes, Accelerate Diagnostics is a public company listed on NAS. |
What is the stock symbol of Accelerate Diagnostics? | Accelerate Diagnostics trades under AXDX ticker. |
When did Accelerate Diagnostics go public? | Accelerate Diagnostics went public in 1996. |
Who are competitors of Accelerate Diagnostics? | Similar companies to Accelerate Diagnostics include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem. |
What is the current market cap of Accelerate Diagnostics? | Accelerate Diagnostics's current market cap is $29.6M |
What is the current revenue of Accelerate Diagnostics? | Accelerate Diagnostics's last 12-month revenue is $12.0M. |
What is the current EV/Revenue multiple of Accelerate Diagnostics? | Current revenue multiple of Accelerate Diagnostics is 5.7x. |
What is the current revenue growth of Accelerate Diagnostics? | Accelerate Diagnostics revenue growth between 2023 and 2024 was -1%. |
Is Accelerate Diagnostics profitable? | Yes, Accelerate Diagnostics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.